Determination of IgG Response Profile in SARS-CoV-2 Patients Using a Multiplex Serological Assay

E. Brochot, Souplet, P. Follet, P. Ponthieu, C. Olivier, G. Even, C. Audebert, R. Malbec
{"title":"Determination of IgG Response Profile in SARS-CoV-2 Patients Using a Multiplex Serological Assay","authors":"E. Brochot, Souplet, P. Follet, P. Ponthieu, C. Olivier, G. Even, C. Audebert, R. Malbec","doi":"10.26420/austinjpublichealthepidemiol.2021.1096","DOIUrl":null,"url":null,"abstract":"Background: Beyond the diagnosis of SARS-CoV-2 infection, tools delivering a global picture of the patients’ humoral response may be of interest for the comprehension of the disease severity and the assessment of the patients’ protection for vaccination strategy. Objectives: Here we use a commercial multiplex serological immunoassay CoViDiag®, based on an array of five different antigens of the virus (the Nucleocapsid, the Spike 1 and Spike 2 subunits, and the RBD and NTD domains of the Spike), to investigate the profile of the IgG humoral response for patients with recent SARS-CoV-2 infection depending on the disease severity outcome, or the time post-PCR. Results: No cross-reaction was observed with the four other seasonal coronaviruses (100% specificity, 0/28). 100% (20/20) of the hospitalized patients PCR-positive to SARS-CoV-2 presented detectable levels of IgGs. 14 days post-PCR diagnosis, 92.3% of the patients, PCR-positive, that did not required hospitalization are presenting IgG (36/39). Interestingly for CoViDiag-positive samples, detectable levels of anti-RBD were found mainly in hospitalized patients (85%, 17/20), while the presence of anti-S1 (60.9%, 28/46) combined with the absence of anti-RBD (6.5%, 3/46) was more characteristic of nonhospitalized patients. Screening campaign group lacked both anti-S1 (18.2%, 4/22) and anti-RBD (4.5%, 1/22). Conclusion: The CoViDiag® IgG assay could be used to evaluate patients’ immunization and improve their management.","PeriodicalId":93417,"journal":{"name":"Austin journal of public health and epidemiology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Austin journal of public health and epidemiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26420/austinjpublichealthepidemiol.2021.1096","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Beyond the diagnosis of SARS-CoV-2 infection, tools delivering a global picture of the patients’ humoral response may be of interest for the comprehension of the disease severity and the assessment of the patients’ protection for vaccination strategy. Objectives: Here we use a commercial multiplex serological immunoassay CoViDiag®, based on an array of five different antigens of the virus (the Nucleocapsid, the Spike 1 and Spike 2 subunits, and the RBD and NTD domains of the Spike), to investigate the profile of the IgG humoral response for patients with recent SARS-CoV-2 infection depending on the disease severity outcome, or the time post-PCR. Results: No cross-reaction was observed with the four other seasonal coronaviruses (100% specificity, 0/28). 100% (20/20) of the hospitalized patients PCR-positive to SARS-CoV-2 presented detectable levels of IgGs. 14 days post-PCR diagnosis, 92.3% of the patients, PCR-positive, that did not required hospitalization are presenting IgG (36/39). Interestingly for CoViDiag-positive samples, detectable levels of anti-RBD were found mainly in hospitalized patients (85%, 17/20), while the presence of anti-S1 (60.9%, 28/46) combined with the absence of anti-RBD (6.5%, 3/46) was more characteristic of nonhospitalized patients. Screening campaign group lacked both anti-S1 (18.2%, 4/22) and anti-RBD (4.5%, 1/22). Conclusion: The CoViDiag® IgG assay could be used to evaluate patients’ immunization and improve their management.
多重血清学检测法测定严重急性呼吸系统综合征冠状病毒2型患者的IgG反应谱
背景:除了诊断严重急性呼吸系统综合征冠状病毒2型感染外,提供患者体液反应全局图的工具可能对理解疾病严重程度和评估患者对疫苗接种策略的保护感兴趣。目的:在这里,我们使用商业多重血清学免疫测定CoViDiag®,基于病毒的五种不同抗原(核衣壳、刺突1和刺突2亚基以及刺突的RBD和NTD结构域),根据疾病严重程度的结果,研究近期严重急性呼吸系统综合征冠状病毒2型感染患者的IgG体液反应谱,或PCR后的时间。结果:未观察到与其他四种季节性冠状病毒的交叉反应(特异性100%,0/28)。100%(20/20)的严重急性呼吸系统综合征冠状病毒2型PCR阳性住院患者出现可检测的IgG水平。在PCR诊断后14天,92.3%的PCR阳性患者(不需要住院治疗)出现IgG(36/39)。有趣的是,对于CoViDiag阳性样本,可检测到的抗RBD水平主要在住院患者中发现(85%,17/20),而抗S1的存在(60.9%,28/46)与抗RBD的缺失(6.5%,3/46)更具非住院患者的特征。筛选运动组同时缺乏抗S1(18.2%,4/22)和抗RBD(4.5%,1/22)。结论:CoViDiag®IgG检测可用于评估患者的免疫情况,提高患者的管理水平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信